Economic Impact of PromarkerD In Vitro Diagnostic Testing on the Management of Chronic Kidney Disease in Type 2 Diabetes: A Budget Impact Analysis.

Published 07/10/2026

Research record: Economic Impact of PromarkerD In Vitro Diagnostic Testing on the Management of Chronic Kidney Disease in Type 2 Diabetes: A Budget Impact Analysis.

Published in Pharmacoecon Open; first publication date 2026-07-10. PMID 42432212.

This literature update records publication metadata from Europe PMC. Consult the original publication for its methods, findings and limitations.

Read the original publication on PubMed

Talk to a Specialist Browse all insights

Review and references

Source

Compiled from public manufacturer materials and regulatory sources. Not independently verified and not reviewed by a named clinician.

Published

2026-07-10

Updated

2026-10-20

Disclaimer

professional use

References